The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26114989 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ho Tsoi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Coenzyme A Ligases, Fatty Acids, Nuclear Receptor Co-Repressor 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Research Fund, the Committee on Research and Conference Grants from the University of Hong Kong, Research Grants Council, Hong Kong General Research Fund.
Abstract (Originalsprache)
BQ323636.1 (BQ), a splice variant of NCOR2, is associated with endocrine therapy resistance and poorer prognosis in ER-positive breast cancer. This study investigates the role of BQ in modulating lipid metabolism to support tumor growth. RNA sequencing of BQ-overexpressing breast cancer cells revealed significant enrichment of fatty acid metabolism pathways (hsa01212 and hsa00061; p < 0.05), with ACSL4 identified as a key target. We show that BQ disrupts the NCOR2-PPARγ interaction, leading to ACSL4 upregulation, which enhances fatty acid oxidation (FAO), acetyl-CoA by 1.8-fold, and ATP production by 2.5-fold to fuel tumor proliferation. BQ also upregulates FASN and SCD, increasing lipids. A metabolites study with mass spectrometry indicated that BQ overexpression increases the fatty acid amount from 47.97 nmol/106 cells to 75.18 nmol/106 cells in MCF7 and from 56.19 nmol/106 cells to 95.37 nmol/106 cells in ZR-75. BQ activates NRF2, which mitigates ROS-induced stress, promoting cell survival. Targeting ACSL4 with the inhibitor PRGL493 reduced ATP production and suppressed tumor growth in vitro and in vivo, without inducing apoptosis, suggesting a cytostatic effect. PRGL493 treatment can reduce BQ overexpressing tumors by 40% in the xenograft model. These results highlight BQ can serve as a transcriptional hub driving lipid metabolism via ACSL4 in breast cancer. Our findings suggest that ACSL4 inhibition could be a novel therapeutic strategy to overcome treatment resistance in high-BQ expressing ER-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Ho Tsoi, Ui-Soon Khoo
Förderung
- General Research Fund
- the Committee on Research and Conference Grants from the University of Hong Kong
- Research Grants Council, Hong Kong General Research Fund
- Committee on Research and Conference Grants from the University of Hong Kong
Zitieren
APA
Tsoi, H., You, C. P., Cheung, K. H., Tse, Y. S., & Khoo, U. S. (2025). The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26114989
Vancouver
Tsoi H, You CP, Cheung KH, Tse YS, Khoo US. The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26114989
BibTeX
@article{Tsoi2025,
author = {Tsoi, Ho and You, Chan-Ping and Cheung, Koei Ho-Lam and Tse, Yin-Suen and Khoo, Ui-Soon},
title = {The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26114989}
}
EUVIMED